Academic
Publications
The MALDI-TOF Mass Spectrometric View of the Plasma Proteome and Peptidome

The MALDI-TOF Mass Spectrometric View of the Plasma Proteome and Peptidome,Glen L. Hortin

The MALDI-TOF Mass Spectrometric View of the Plasma Proteome and Peptidome   (Citations: 100)
BibTex | RIS | RefWorks Download
Background: Matrix-assisted laser desorption/ioniza- tion time-of-flight mass spectrometry (MALDI-TOF MS) and the related technique, surface-enhanced laser desorption/ionization (SELDI)-TOF MS, are being ap- plied widely to analyze serum or plasma specimens for potential disease markers. Methods: Reports on the basic principles and applica- tions of MALDI-TOF MS were reviewed and related to information on abundance and masses of major plasma proteins. Outcomes: MALDI-TOF MS is a particle-counting method that responds to molar abundance, and ranking of plasma proteins by molar abundance increases the rank of small proteins relative to traditional ranking by mass abundance. Detectors for MALDI-TOF MS aug- ment the bias for detecting smaller components by yielding stronger signals for an equivalent number of small vs large ions. Consequently, MALDI-TOF MS is a powerful tool for surveying small proteins and peptides comprising the peptidome or fragmentome, opening this new realm for analysis. It is complementary to techniques such as electrophoresis and HPLC, which have a bias for detecting larger molecules. Virtually all of the potential markers identified by MALDI-TOF MS to date represent forms of the most abundant plasma proteins. Conclusions: Analyses of serum or plasma by MALDI- TOF MS provide new information mainly about small proteins and peptides with high molar abundance. The spectrum of observed proteins and peptides suggests value for applications such as assessment of cardiovas- cular risk, nutritional status, liver injury, kidney failure, and systemic immune responses rather than early detec- tion of cancer. Extending analysis by MALDI-TOF MS to lower abundance components, such as markers for
Published in 2006.
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
    • ... Early detection was shown to greatly improve the efficacy of cancer treatment, yet detection is often only possible after the appearance of the first clinical symptoms, which in some cancers occurs too late for successful intervention. This is largely due to the absence of specific and sensitive tests that allow early screening and monitoring of cancerous states. Therefore, the discovery of novel tumor biomarkers is increasingly considered critical to improving cancer treatment. In the past decade, many studies have focused on biomarker discovery. One of the most promising sources for biomarker discovery is the human blood, in particular serum and plasma, which can reflect many events in the body, in real time. Yet, despite immense efforts, only a very small number of plasma proteins have been proven to have diagnostic value ...

    Meital Cohenet al. Serum Apolipoproteins CI and CIII Are Reduced in Stomach Cancer Patien...

    • ...With recent advances in proteomic technologies, protein and peptide biomarker discovery is now a major area of proteome research [5, 6]. Profiling methods such as surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry (MS) and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS analyses of blood samples are promising techniques for biomarker discovery [7]...

    Hiroshi UmemuraAkiraet al. Identification of a high molecular weight kininogen fragment as a mark...

    • ...These methods are also not ideal for particularly large molecules, which are better detected with electrophoresis and immunoblotting [62]...

    Cody L Westonet al. Detection of cancer cells in the cerebrospinal fluid: current methods ...

    • ...In fact, we noticed consistent literature reports [12] for a protein (at 11.696 kDa) with this family of modifications, and further experimental testing validated that identification and assignment to serum amyloid A. Thus, the combination of better data processing and analysis improved biomarker ID capabilities [11,12]...
    • ...In fact, we noticed consistent literature reports [12] for a protein (at 11.696 kDa) with this family of modifications, and further experimental testing validated that identification and assignment to serum amyloid A. Thus, the combination of better data processing and analysis improved biomarker ID capabilities [11,12]...

    Karl W. Kuschneret al. A Bayesian network approach to feature selection in mass spectrometry ...

    • ...Samples may require preparation steps to fractionate for complexity reduction, protein or peptide extraction and removal of lipids and salt [9]...

    Ediri Sidesoet al. Assessing the Quality and Reproducibility of a Proteomic Platform for ...

Sort by: